Scientific research drives innovation at Novartis. Our researchers work to push the boundaries of science, broaden our understanding of diseases and develop novel products with significant benefits for patients. We are focusing on faulty molecular pathways and therapeutic areas where we see the greatest unmet medical need and believe the scientific tools to address these needs are within reach.
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. More than 6 000 scientists and physicians prioritize work based on areas of greatest patient need and scientific understanding of disease.
Strategic alliances with academia and other companies strengthen our preclinical pipeline. We carry out research at Novartis locations and at partner institutions around the world:
Friedrich Miescher Institute for Biomedical Research (FMI)
Founded in 1970, the Friedrich Miescher Institute is devoted to fundamental biomedical research and focuses on epigenetics, growth control and neurobiology.
The Genomics Institute of the Novartis Research Foundation (GNF)
La Jolla, California, US
Located in San Diego’s BioMedical research center, GNF is well-known for developing novel technology to drive cutting-edge drug discovery research, identify new biological pathways and discover mechanisms underlying human disease.
Novartis Institutes for BioMedical Research (NIBR) – Basel
Co-located with our corporate world headquarters, NIBR Basel is an integral part of the BioValley, Europe's biotechnology hub. Drug discovery here focuses on autoimmunity, transplantation, and inflammation, as well as musculoskeletal diseases, neuroscience, and oncology.
Novartis Institutes for BioMedical Research (NIBR) – Headquarters
Cambridge, Massachusetts, US
NIBR Cambridge is located in the midst of multiple renowned academic research institutions and innovative biotech companies. The NIBR headquarters is home to research in the areas of oncology, ophthalmology, and cardiovascular and metabolic related diseases.
Novartis Institutes for BioMedical Research (NIBR) – East Hanover
East Hanover, New Jersey, US
Located on the same campus as our US Pharmaceuticals Division headquarters, NIBR East Hanover focuses on research in cardiovascular and metabolic diseases. It is also home to the Novartis Knowledge Center (NKC) and information analysis, preclinical safety, and metabolism and pharmacokinetics groups.
Novartis Institutes for BioMedical Research (NIBR) – Emeryville
Emeryville, California, US
Located in the San Francisco Bay area, the NIBR Emeryville campus focuses on early discovery and research activities as a hub for infectious disease research, with additional expertise in structural and biophysical chemistry, computer-aided drug design and protein engineering across many disease areas.
Novartis Institutes for BioMedical Research (NIBR) – Shanghai
Novartis has an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park in the midst of an emerging cluster of innovative academic, biotech and pharmaceutical research institutions. Research focuses on infectious causes of cancer primarily found in Asia and includes efforts in discovery chemistry and biomarker research.
Dedicated to finding new medicines to treat neglected, infectious diseases. As a small-molecule drug discovery research institute, it combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases, including Dengue Fever, Human African Trypanosomiasis and Malaria.
The development site in East Hanover, New Jersey consists of: Technical Research & Development, Drug Regulatory Affairs, Integrated Information Sciences * Informatics, Drug Safety & Epidemiology, Clinical & Medical Services, Modeling & Simulation, Strategic Sourcing, Human Resources, Finance and Operations. All global franchises are represented: Cardiovascular & Metabolism, Neuroscience & Ophthalmics, Immunology & Infectious Diseases, Respiratory, and Mature Products.
The Development site in Basel consists of: Technical Research & Development, Drug Regulatory Affairs, Integrated INformation Sciences & Informatics, Drug Safety & Epidemiology, Clinical & Medical Services, Modeling & Simulation, Strategic Sourcing, Human Resources, Finance and Operations. Additionally, all franchises are represented: Cardiovascular & Metabolism, Neuroscience & Ophthalmics, Immunology & Infectious Diseases, Respiratory, and Mature Products.
The Novartis site in Changshu is situated about 80 km northwest of Shanghai, near the major city Suzhou. Development is represented in Changshu through the Chemical and Analytical Development, a Technical Research & Development Department. The focus of the Changshu site is on the process and analytical research and development of innovative experimental drug substances as well as their manufacturing technologies.
Novartis’ Development site in India is located in Hyderabad. This Development center consists of Medical Scientific Communication and Documentation, Electronic Data Management, Biometrics, Technical Research and Development, Drug Regulatory Affairs, Drug Safety and Epidemiology, and Development Informatics.
Novartis has a development center in Shanghai’s Zhangjiang Hi-Tech Park. Development is represented at the Shanghai site by all the key pillars of exploratory and confirmatory development: Translational Sciences, Biomarker Development and Drug Metabolism and Pharmacokinetics and Technical Research and Development.
Novartis’ Development site in Japan is located in Nishi-Azabu, Tokyo. The Development representation of this site consists of Translational Science, Technical Research and Development, Clinical Development (Cardiovascular and Metabolism, Neuroscience and Ophthalmics, Immunology and Infectious Diseases, Respiratory and Oncology), Drug Safety and Epidemiology Drug Regulatory Affairs.